Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega-3 fatty acids. If fenofibate-related side effects occur, or a statin is required to control low-density lipoproteincholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment.

Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids / Musolino, A; Panebianco, M; Zendri, E; Santini, M; DI NUZZO, Sergio; Ardizzoni, A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 145:1(2009), pp. 84-86. [10.1111/j.1365-2141.2009.07596.x]

Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids.

MUSOLINO A;DI NUZZO, Sergio;
2009-01-01

Abstract

Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega-3 fatty acids. If fenofibate-related side effects occur, or a statin is required to control low-density lipoproteincholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment.
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids / Musolino, A; Panebianco, M; Zendri, E; Santini, M; DI NUZZO, Sergio; Ardizzoni, A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 145:1(2009), pp. 84-86. [10.1111/j.1365-2141.2009.07596.x]
File in questo prodotto:
File Dimensione Formato  
Br J Haematol 2009.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 59.28 kB
Formato Adobe PDF
59.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2288336
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact